Inventor

Jin Q. Cheng

Inventor

Tampa, FL, US

Overview

2012–2020

Patent span

Human necessities

Primary field (CPC A)

Patents· 37 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes25%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%

G01NInvestigating or analysing materials by determining their chemical or physical properties14%

C07HSugars9%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms9%

C07KPeptides6%

C07DHeterocyclic compounds4%

C07CAcyclic or carbocyclic compounds2%

C12NMicroorganisms or enzymes2%

C12YEnzymes2%

PatentTitleYear

10,780,104Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof2020 10,744,148Methods of treating breast cancer that overexpress AKT kinase2020 10,076,534Effective treatment of ovarian cancer using triciribine and related compounds2018 9,896,668'Substrate-mimetic AKT inhibitor'2018 9,655,914'Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof'2017 9,518,079'Effective treatment of tumors and cancer with triciribine and related compounds'2016 9,511,084'Compositions including triciribine and methods of use thereof'2016 9,498,492'Compositions including triciribine and taxanes and methods of use thereof'2016 9,486,470'Compositions including triciribine and one or more platinum compounds and methods of use thereof'2016 9,486,492'Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof'2016 9,486,522'Compositions including triciribine and trastuzumab and methods of use thereof'2016 9,457,040'Effective treatment of esophageal adenocarcinoma using triciribine and related compounds'2016 9,453,049'Substrate-mimetic Akt inhibitor'2016 9,433,635'Effective treatment of ovarian cancer using triciribine and related compounds'2016 9,410,956'Micro-RNA profiling in ovarian cancer'2016 9,359,347'Inhibitors of Akt/PKB with anti-tumor activity'2016 9,265,783'Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof'2016 9,211,299'Compositions including triciribine and one or more platinum compounds and methods of use thereof'2015 9,192,645'Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof'2015 9,186,403'Compositions including triciribine and trastuzumab and methods of use thereof'2015 9,150,604'Effective treatment of esophogeal adenocarcinoma using triciribine and related compounds'2015 9,115,162'Effective treatment of tumors and cancer with triciribine and related compounds'2015 9,101,641'Compositions including triciribine and taxanes and methods of use thereof'2015 8,906,869'Effective treatment of ovarian cancer using triciribine and related compounds'2014 8,901,086'Compositions including triciribine and methods of use thereof'2014 8,865,666'Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof'2014 8,828,451'Akt sensitization of cancer cells'2014 8,822,524'Substrate-mimetic Akt inhibitor'2014 8,691,779'Compositions including triciribine and taxanes and methods of use thereof'2014 8,673,868'Compositions including triciribine and one or more platinum compounds and methods of use thereof'2014 8,673,867'Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof'2014 8,623,834'Compositions including triciribine and trastuzumab and methods of use thereof'2014 8,476,241'Effective treatment of esophogeal adenocarcinoma using triciribine and related compounds'2013 8,435,959'Effective treatment of tumors and cancer with triciribine and related compounds'2013 8,435,550'Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device'2013 8,183,249'Inhibitors of AKT/PKB with anti-tumor activity'2012 8,178,502'Effective treatment of esophogeal adenocarcinoma using triciribine and related compounds'2012

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2012–2020Patents assigned to UNIV SOUTH FLORIDA (36)· patent assignee history

2012–2016Patents assigned to CHENG JIN Q (15)· patent assignee history

2012–2016Patents assigned to SEBTI SAID M (12)· patent assignee history

2012–2020Based in Tampa, FL, US· patent location history

2013Based in San Jose, CA, US· patent location history

2014–2018Patents assigned to UNIV YALE (3)· patent assignee history

2014–2016Patents assigned to HAMILTON ANDREW D (2)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
UNIV SOUTH FLORIDA	36	2012–2020
CHENG JIN Qself	15	2012–2016
SEBTI SAID M	12	2012–2016
UNIV YALE	3	2014–2018
HAMILTON ANDREW D	2	2014–2016

Locations

Location	Patents	Span
Tampa, Florida, US	36	2012–2020
San Jose, California, US	1	2013